{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:11Z","timestamp":1787020151254,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have provided significant benefits in cancer treatment, but they could develop immune-related adverse events (irAE). ICI-associated renal adverse effects are rare and tubulointerstitial nephritis (TIN) is the most common in the renal irAE. However, only a few case reports of renal vasculitis associated with ICI have been reported. In addition, the characteristics of infiltrating inflammatory cells of ICI-associated TIN and renal vasculitis have been uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 65-year-old man received immune checkpoint inhibitors (ICIs), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and anti-PD-1 (programmed cell death 1) antibodies for aggravated metastatic malignant melanoma. About 1\u2009week after the second administration of nivolumab and ipilimumab, acute kidney injury developed. A renal biopsy was performed that showed TIN and non-necrotizing granulomatous vasculitis in interlobular arteries. Massive CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells and CD163\n                      <jats:sup>+<\/jats:sup>\n                      macrophages infiltrated both tubulointerstitium and interlobular arteries. Many infiltrating cells tested positive for Ki-67 and PD-1 ligand (PD-L1), but negative for PD-1. In CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells, CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells were predominantly infiltrated, and these cells were positive for Granzyme B (GrB) and cytotoxic granule TIA-1, but negative for CD25, indicating antigen-independent activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Infiltration of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells was noted without obvious CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>+<\/jats:sup>\n                      regulatory T (Treg) cells. His renal dysfunction recovered within 2\u2009months of treatment with prednisolone in addition to discontinuation of nivolumab and ipilimumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We herein reported a case of ICI-related TIN and renal granulomatous vasculitis with infiltration of massive antigen-independent activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and CD163\n                      <jats:sup>+<\/jats:sup>\n                      macrophages, and none or few CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>+<\/jats:sup>\n                      Treg cells. These infiltrating cells might be a characteristic of the development of renal irAE.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-023-03091-8","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T01:03:07Z","timestamp":1678323787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Kenta","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Takakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kajimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Kunugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"1","key":"3091_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"9","key":"3091_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"4","key":"3091_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374.","journal-title":"Ann Oncol"},{"issue":"3","key":"3091_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"2","key":"3091_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3091_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","volume":"5","author":"SM Herrmann","year":"2020","unstructured":"Herrmann SM, Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep. 2020;5(8):1139\u201348.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"3091_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"3091_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11523-016-0426-9","volume":"11","author":"JW Vandiver","year":"2016","unstructured":"Vandiver JW, Singer Z, Harshberger C. Severe hyponatremia and immune nephritis following an initial infusion of Nivolumab. Target Oncol. 2016;11(4):553\u20136.","journal-title":"Target Oncol"},{"issue":"6","key":"3091_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for Cancer immunotherapy. Cancers (Basel). 2021;13(6):1440.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3091_CR10","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692\u2013700.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3091_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis with Programmed Cell Death 1 inhibitor therapy in lung Cancer patients. Am J Kidney Dis. 2016;68(2):287\u201391.","journal-title":"Am J Kidney Dis"},{"key":"3091_CR12","doi-asserted-by":"publisher","first-page":"964335","DOI":"10.3389\/fmed.2022.964335","volume":"9","author":"EM Moss","year":"2022","unstructured":"Moss EM, Perazella MA. The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. Front Med (Lausanne). 2022;9:964335.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"3091_CR13","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37(9):2579\u201384.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3091_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216\u201322.","journal-title":"JAMA Neurol"},{"issue":"1","key":"3091_CR15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12882-019-1552-2","volume":"20","author":"M Lemoine","year":"2019","unstructured":"Lemoine M, Dilly B, Curie A, Hebert V, Laurent C, Hanoy M, et al. Ipilimumab-induced renal granulomatous arteritis: a case report. BMC Nephrol. 2019;20(1):366.","journal-title":"BMC Nephrol"},{"issue":"6","key":"3091_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","volume":"74","author":"AJ Gallan","year":"2019","unstructured":"Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ. Renal Vasculitis and Pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis. 2019;74(6):853\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3091_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cytogfr.2006.07.003","volume":"17","author":"HP Kim","year":"2006","unstructured":"Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system. Cytokine Growth Factor Rev. 2006;17(5):349\u201366.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"3091_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00428-017-2264-2","volume":"472","author":"M Kobayashi","year":"2018","unstructured":"Kobayashi M, Ogawa E, Okuyama R, Kanno H. In vasculitis of small muscular arteries, activation of vessel-infiltrating CD8 T cells seems to be antigen-independent. Virchows Arch. 2018;472(2):271\u20139.","journal-title":"Virchows Arch"},{"issue":"13","key":"3091_CR19","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2011-07-369736","volume":"119","author":"JK Tietze","year":"2012","unstructured":"Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood. 2012;119(13):3073\u201383.","journal-title":"Blood"},{"issue":"9","key":"3091_CR20","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1681\/ASN.2015050511","volume":"27","author":"VP O'Reilly","year":"2016","unstructured":"O'Reilly VP, Wong L, Kennedy C, Elliot LA, O'Meachair S, Coughlan AM, et al. Urinary soluble CD163 in active renal Vasculitis. J Am Soc Nephrol. 2016;27(9):2906\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"3091_CR21","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.2169\/internalmedicine.0444-17","volume":"57","author":"A Tabei","year":"2018","unstructured":"Tabei A, Watanabe M, Ikeuchi H, Nakasatomi M, Sakairi T, Kaneko Y, et al. The analysis of renal infiltrating cells in acute Tubulointerstitial nephritis induced by anti-PD-1 antibodies: a case report and review of the literature. Intern Med. 2018;57(21):3135\u20139.","journal-title":"Intern Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-023-03091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-023-03091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T01:05:05Z","timestamp":1678323905000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-023-03091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3091"],"URL":"https:\/\/doi.org\/10.1186\/s12882-023-03091-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have obtained consent from the patient reported in this article for publication of the information about him that appears within this Case Report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}